Docetaxel Prednisone

Eisenberger MA, DeWit R, Berry W, et al. A multicenter phase 111 comparison of docetaxel + prednisone and mitoxantvone + prednisone in patients with hormone-refractory prostate cancer. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol. 22, (July 15 Supplement), 2004 2s (abstract no. 4). 

Teva Pharmaceutical Industries and OncoGenex Technologies (2010) Comparison of docetaxel jrednisOTie to docetaxel/prednisone in combination with OGX-011 in men with prostate cancCT (SYNERGY). Available at http //clinicaltrials.gov/ct2/show/NCT01188187. Last accessed 25 July 2011. US National Library of Medicine, Bethesda... 

Chemotherapy, with docetaxel and prednisone or docetaxel and estramustine, improves survival in patients with hormone-refractory prostate cancer. Patients with hormone-refractory prostate cancer should be considered for entry into clinical trials investigating new therapies for prostate cancer. 

Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med. 2004 351(15) 1502—1512. 

Docetaxel, 75 mg/m2 every 3 weeks, combined with prednisone, 5 mg twice daily, has been shown to prolong survival in hormone-refractory metastatic prostate cancer. The most common adverse events were nausea, alopecia, and myelosuppression. Docetaxel can also cause fluid retention and peripheral neuropathy. 

Petrylak, D.P. et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N. Engl. Med., 351,1513-1520, 2004. 

XRP6258 (cabazitaxel, TXD-258, RPR-116258A) 61 (Sanofi-Aventis) is undergoing Phase III trials in combination with prednisone as a treatment of hormone resistant prostate cancer in patients who had previously been treated with a paclitaxel 60.124 XRP62 5 8 61134,135 is a semi-synthetic derivative of the paclitaxel 60 with a docetaxel-like side chain which, like larotaxel 59, has a low affinity for the P-glycoprotein drug efflux pump. 

Miller VA, Rigas JR, Francis PA, Grant SC, Pisters KM, Venkatraman ES, Woolley K, Heelan RT, Kris MG. Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995 75(4) 968-72. 

A 25% incidence of grade 2 or more severe immunological reactions to docetaxel has been reported after the use of oral prednisone (100 mg orally before treatment and 50 mg once on the morning of treatment and the following 2 days) in 20 patients with non-small-cell lung cancers (8). No other premedications were given routinely. If infusion-related symptoms occurred, the infusion was interrupted and diphenhydramine was given. On subsequent cycles those patients then were routinely premedicated with diphenhydramine 25 or 50 mg intravenously and cimetidine 300 mg intravenously. 

Cytotoxic drags that have been used alone and in combination as adjuvant therapy in breast cancer include doxorubicin, epirubicin, cyclophosphamide, methotrexate, fluorouracil, paclitaxel, docetaxel, melphalan, prednisone, vinorelbine, and vincristine. The most common combination chemotherapy regimens employed in the adjuvant and metastatic setting are listed in Table 125-11. 

On May 19, 2004, docetaxel was approved for the treatment of metastatic prostate cancer. The approval was based on the TAX327 study, a randomized, multicenter global clinical trial enrolling over 1000 men with metastatic, hormone-refractory prostate cancer. The study compared docetaxel 75 mg/m every 3 weeks and prednisone 5 mg twice a day with docetaxel 35 mg/m weekly five out of six weeks and prednisone 5 mg twice a day and mitoxantrone 75 ng/m every 3 weeks and prednisone 5 mg twice a day. Docetaxel, in combination with prednisone, given every 3 weeks showed a survival advantage of approximately 2.5 months over the control group in the trial p =. 009). The most common adverse events reported were nausea, alopecia, and bone marrow suppression. In addition, fluid retention and peripheral neuropathy, known effects of docetaxel, were... 

Docetaxel and prednisone have recently been shown to improve survival in hormone-refractory metastatic prostate cancer and should be considered standard therapy. Single agents with modest activity in prostate cancer include cyclophosphamide, estramustine, 5-fluorouracil, methotrexate, dacarbazine, mitoxantrone, doxorubicin, pachtaxel, gemcitabine, vinorelbine, and cisplatin. If disease stabilization is included as a favorable response, response rates np to 46% have been reported. Several trials have evalnated the varions combination regimens containing the most active single agents. ... 

Both estramustine combined with vinblastine and mitoxantrone combined with prednisone are active combination regimens for refractory prostate cancer. Although estramustine as a single agent produced similar response rates to other available chemotherapy agents, development of estramustine combinations (such as estramustine plus vinblastine or estramustine plus docetaxel) continued when its mechanism of action was discovered to involve microtubule proteins rather than alkylation. ... 

Microsomes prepared from patients treated with pentobarbital and/or phenobarbital are reported to have stimulated docetaxel metabolism strikingly whereas those prepared from a patient taking prednisone did not. In a study in patients with metastatic prostatic cancer, prednisone did not significantly affect the pharmacokinetics of docetaxel. ... 

A study in 9 patients with a variety of malignant diseases found that treatment with antineoplastics reduced the absorption of a single 160-mg oral dose of verapamil. The verapamil AUC in 8 patients was reduced by 40% (range 7 to 58%), and one patient conversely had a 26% increase. Five patients reeeived a modified COPP regimen (cyclophosphamide, vincristine, procarbazine, prednisone) and four received VAC (vindesine, doxornbicin, cisplatin). It is believed that these antineoplastics damage the lining of the upper part of the small intestine, which impairs the absorption of verapamil. The clinical relevance of this reduction does not appear to have been studied. Note that verapamil may affect levels of anthracyclines , (p.611), etoposide , (p.631), and possibly docetaxel , (p.662). In addition, nifedipine may affect the levels of vincristine , (p.671). 

Chi KN, Hotte SJ, Yu EY et al (2010) Randomized phase II study of docetaxel and prednisone with ot without OGX-OII in patients with metastatic castration-resistant prostate cancer. J Qin Oncol 28 4247-4254... 

---